Condition
Schizophrenia Spectrum
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (3)
P 1 (1)
Trial Status
Not Yet Recruiting2
Completed2
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07795554Not ApplicableNot Yet RecruitingPrimary
The Safety and Effectiveness of dTMS for Reducing Antipsychotic-induced Weight Gain
NCT07134816Not ApplicableNot Yet Recruiting
Cost-utility Study of Cognitive-behavioral Management of Auditory Hallucinations in Schizophrenic Disorder
NCT04922593Phase 1Completed
Relative Bioavailability of LY03010 Compared to Listed Drug
NCT02498236Not ApplicableCompletedPrimary
Target Engagement for Oxytocin: Dose Ranging Study
Showing all 4 trials